Last reviewed · How we verify
Multicentre, Double-Dummy, Randomized, Double-Blind Comparison Between Mitiglinide and Nateglinide in the Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of Mitiglinide compared to Nateglinide for the treatment of type 2 diabetes.
Details
| Lead sponsor | Kissei Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 291 |
| Start date | 2006-08 |
| Completion | 2007-07 |
Conditions
- Diabetes
Interventions
- Mitiglinide
Primary outcomes
- Hemoglobin A1C (HbA1C) — -2, 0, 4, 8, 10, 12, 16, 20 week